These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784 [TBL] [Abstract][Full Text] [Related]
25. Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Duska LR; Garrett A; Eltabbakh GH; Oliva E; Penson R; Fuller AF Gynecol Oncol; 2002 Jun; 85(3):459-63. PubMed ID: 12051874 [TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
27. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744 [TBL] [Abstract][Full Text] [Related]
28. Prolonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report. Di Vagno G; Cormio G; Loverro G; Melilli GA; Di Gesù G; Selvaggi L J Chemother; 1998 Oct; 10(5):418-21. PubMed ID: 9822362 [TBL] [Abstract][Full Text] [Related]
29. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma]. Zhao XD; Zhang Y; He SR; Yang L Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810 [TBL] [Abstract][Full Text] [Related]
30. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992 [TBL] [Abstract][Full Text] [Related]
31. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972 [TBL] [Abstract][Full Text] [Related]
32. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603 [TBL] [Abstract][Full Text] [Related]
33. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399 [TBL] [Abstract][Full Text] [Related]
34. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P; J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064 [TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa. Cass I; Resnik E; Chambers JT; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE Gynecol Oncol; 1996 Jun; 61(3):309-14. PubMed ID: 8641607 [TBL] [Abstract][Full Text] [Related]
38. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721 [TBL] [Abstract][Full Text] [Related]
39. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107 [TBL] [Abstract][Full Text] [Related]
40. Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Mok JE; Kim YM; Jung MH; Kim KR; Kim DY; Kim JH; Kim YT; Nam JH Int J Gynecol Cancer; 2006; 16(1):101-5. PubMed ID: 16445618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]